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Abstract
A serosurvey of anti-Ebola Zaire virus
nucleoprotein IgG prevalence was carried
out among Ebola virus disease survivors
and their Community Contacts in Bombali
District, Sierra Leone. Our data suggest that
the specie of Ebola virus (Zaire) responsible
of the 2013-2016 epidemic in West Africa
may cause mild or asymptomatic infection
in a proportion of cases, possibly due to an
efficient immune response. 
Introduction
Ebola Virus Disease (EVD) spreads in
communities through person-to-person
transmission, with infection resulting from
direct contact with blood, secretions, other
body fluids or organs, and indirect contact
with contaminated environmental materials
or infected animals. In Sierra Leone, a total
of 8704 confirmed cases and 3589 deaths
were reported by the end of December
2015,1 of which 307 (221 deaths) were
among health care workers (HCWs).2 In
Bombali District, located in the northern
region of the country, a total of 1050 con-
firmed EBV cases have been cumulatively
reported since May 2013 to the end of
December 2015. Retrospective serologic
data3 suggest that EBOV might have been in
circulation in Sierra Leone since 2006.
The role of antibody responses in viral
clearance and protection against Ebola
Virus (EBOV) in humans is not fully under-
stood. Among EVD survivors, antibodies
appear as early as day-5 after symptom
onset, peak 2 weeks after recovery, then
decline slowly over several years.4-7 In
patients with fatal outcome, antibody titers
are low or absent.8 The presence of
detectable anti-EBOV antibodies in asymp-
tomatic individuals suggests exposure and a
putative role of antibody response in the
control of EVD and provides information
on EBOV seroprevalence in at risk popula-
tions.9 Monitoring anti-EBOV antibodies in
EVD-community contacts (CCs) of index
cases is crucial for assessing immune pro-
tection against EBOV. Due to the large
number of infected HCWs, evaluation of
anti-Ebola antibodies in this group is a use-
ful tool for measuring the risk of occupa-
tional exposure to EBOV.
The aim of the study was to assess the
extent of asymptomatic or mild cases of
EBOV infection among the CCs of labora-
tory confirmed EVD cases (survivors or
deceased) and in HCWs from health facili-
ties not involved in the management of
EVD cases. 
Materials and Methods
Study populations
The study was conducted between
February and March 2015 in the rural area
of Sanda Loko Chiefdom, in the villages of
Kamalo, Maron and Makasa (Figure 1) in
the context of Ebola survivor Mobile Health
Clinic program aimed to provide integrated
primary healthcare services to address the
medical and psychosocial needs of Ebola
survivors living in areas with low medical
coverage.10
A total of 6 EVD-deaths and 10 EVD-
survivors were reported (Table 1). EVD
cases were reported from Kamalo (4 deaths
and 10 survivors) and Maron (2 deaths) vil-
lages, whereas no cases were reported from
Makasa village (Table 2). EVD survivors
were defined as individuals who showed
EVD clinical signs or symptoms with
EBOV infection confirmed by RT-PCR
assay. Considering the organization of the
local rural society, CCs were individuals
from communities placed under quarantine. 
In addition, seventy-nine HCWs were
included in this study from Holy Spirit
Hospital (n=59) and Loreto Clinic (n=20),
two religious health care facilities in
Makeni municipality (headquarter of
Bombali District) that were not involved
in the management of EVD cases (Table 1).
The definition of HCWs included physi-
cians, nurses, laboratory technicians,
administrative personnell and cleaners
(Table 1).
The Ethical Review Board of the
Ministry of Health and Sanitation of Sierra
Leone approved this study, and participants
gave their approval by signing or finger-
printing a written consent form.
Demographic data and information about
clinical history were collected using pre-
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tested questionnaires before obtaining 4 ml
of peripheral blood by venipuncture.
Anti Ebola virus antibody level
Anti-Zaire Ebola Nucleoprotein
(ZEBOV-NP) IgG antibodies were quanti-
fied using Enzyme-Linked Immunosorbent
assay (ELISA) by a commercial kit
(AE320620-1, Alpha Diagnostic
International [ADI], Texas, USA), accord-
ing to the manufacturer’s instructions.
Positive control and calibrators provided by
the kit were used in each test run. Optimal
sample dilution was previously determined
at 1:500 by testing 68 positive control plas-
ma samples from EVD-survivors and 10
negative control plasma samples from
expatriates not exposed to Ebola infection. 
Threshold index to discriminate posi-
tive and negative antibody reactivity to
ZEBOV NP was calculated following man-
ufacturer’s instructions. 
Statistical analysis
Data were collected and entered in a
customized template in EpiData software
version 3.1. The prevalence was calculated
by dividing the number of seropositive
cases by the number of examined individu-
als. Comparison among frequency of
seropositive CCs from different villages
was performed by one-tail Fisher’s exact
test assuming the hypothesis of seropreva-
lence association.
Results and Discussion
Among Sanda Loko EVD survivors, all
those enrolled from Kamalo were ZEBOV-
NP-IgG positive (n=4/4). Anti-ZEBOV-NP-
IgG were detected in 12 out of the 105 test-
ed CCs (11.4% seroprevalence rate) (Table
1). As described in Table 2, the seropreva-
lence for ZEBOV-NP-IgG in CCs from dif-
ferent villages was 5.9% (n=3/51) in
Kamalo, 20.0% (n=7/35) in Maron, and
10.5% (n=2/19) in Makasa. 
Among HCWs (Table 1), no ZEBOV-
seropositive cases were found in the Loreto
Clinic group (n=0/20), whereas 3 seroposi-
tive cases (1 nurse and 2 cleaners) out of 59
(5.8%) were found at the Holy Spirit
Hospital. Overall, the seroprevalence
among HCWs was 3.8% (n=3/79).
ZEBOV-seropositive CCs did not report
fever or other symptoms/signs suggestive of
EVD during the previous 8 months. Three
of them reported mild, non-specific symp-
toms, including headache (n=1), joint pain
(n=1), or both (n=1). Risk behaviours, such
as hunting activity in the forest, or partici-
pating in a burial service during the past 8
months, were reported by one and two per-
sons respectively. 
Although the knowledge of Ebola
dynamics, pathogenesis and clinical course
is improving, some aspects remain unclear,
including the role for naturally-acquired
humoral immunity. 
The influence of humoral immunity on
EVD outcome was observed in Gabon8 and
confirmed by a serosurvey in Uganda.7 A
larger EBOV serosurvey in Gabon9 showed
significant seroprevalence across the coun-
try even in areas considered Ebola-free, and
raised important questions about EBOV
spread, virulence and the existence of natu-
ral protective immunization.
The overall seroprevalence rate among
asymptomatic CCs in the area of Sanda
Loko Chiefdom was 11.4% with significant
differences observed among the three vil-
lages. Anti-EBOV-positive subjects were
found in all villages with or without con-
firmed EVD cases. Interestingly, the highest
seroprevalence rates was observed in vil-
lages with the lowest incidence of EVD
cases (P<0.05, Table 2) suggesting that
EBOV circulated in those populations with-
out causing disease.
In this paper we report a high sero-
prevalence in asymptomatic CCs of Sanda
Loko Chiefdom although we have recently
shown that only 2.6% (10 of 388) of asymp-
tomatic members of Ebola-affected house-
holds had evidence of Ebola virus infection
in Sierra Leone.11 The extend of asymp-
tomatic EBOV infection is still unclear and
several studies reported a wide variability
of seroprevalence (from 1% to 46%),9,12-14
among the household and CCs. This high
variability can be ascribed to the different
antigens and assays used and also the defi-
nition of contact varied in the studies.
The seroprevalence rate among all
HCWs was 3.8% even if the health facilities
where they worked were not included in the
network for managing EVD cases. We can-
not rule out that they may have been
exposed to EVD outside the work place.
The observed moderate grade of EBOV
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Table 1. Prevalence of ZEBOV-seropositivity in EVD survivors, community contacts and
health care workers.
                                              N      Tested (n)     Seropositives (n)      Seroprevalence (%)
Sanda Loko EVD-survivors            10*                 4                                    4                                             100
Sanda Loko EVD deaths                  6                    -                                    -                                               -
Sanda Loko CCs                               NA                105                                12                                           11.4
Total HCWs                                        79                 79                                   3                                             3.8
Holy Spirit Hospital                       59                 59                                   3                                             5.8
Loreto Clinic                                   20                 20                                   0                                             0.0
*4 survivors were enrolled and tested in this study. NA, not available.
Table 2. EVD deaths and survivors, community contacts and seroprevalence in Sanda
Loko Chiefdom villages.
Village       Deaths        Survivors       CCs              Anti-ZEBOV           Seroprevalence 
                     (n)               (n)           (n*)          positive CCs (n)        (%) among CCs
Kamalo                  4                        10°                   51                                 3                                         5.9#
Maron                    2                          0                     35                                 7                                        20.0
Makasa                  0                          0                     19                                 2                                        10.5
*CC (n) refers to the number of Community Contacts included in this study; °four survivors were enrolled and tested in this study; #P<0.05.
Figure 1. Maps of Sierra Leone, Bombali District and Sanda Loko Chiefdom. Kamalo
and Makasa villages are reported in local language as Kamalu and Makassa respectively. 
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transmission in HCWs needs further analy-
sis of larger groups, along with assessing
the adherence to use of personal protection
(gowns, gloves, masks). This data is consis-
tent with previous serosurvey performed in
Gabon9 and led to hypothesize that the host-
EBOV interaction might determine the
development of specific antibodies capable
to control the infection, leading to mild or
asymptomatic EVD. 
Our findings that anti-ZEBOV-IgG was
detected in both EVD-survivors and CCs,
although at different prevalence rates, sug-
gests that the immunity, previously reported
as persistent among survivors,7 may be
important for protection that allowed sub-
clinical disease among CCs.
Conclusions
Our study provides significant new
insight into population exposure to EBOV
and outcomes of virus infection. This caus-
es us to question the assumption that EBOV
is highly fatal. Instead, EBOV, similar to
Lassa Fever virus15,16 and many other viral
pathogens, may have high fatality as a pro-
portion of clinical cases but relatively high
seroprevalence among persons without evi-
dent disease arguing the fatality rate is actu-
ally lower than has been predicted. These
findings raise important questions about
EBOV pathogenicity and argue that some
individuals have achieved long lasting pro-
tection following attenuated infection7 that
should be taken in account for vaccine pro-
grams. 
There is a strong rationale for expand-
ing the serological screening of exposed
populations and HCWs in countries affect-
ed by EVD to understand their risk of infec-
tion and to guide the implementation of
quarantine when needed, and vaccine pro-
grams when available. 
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